News | August 24, 2021
U.S. FDA approval of KORSUVA injection
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
Therapy recently approved in Canada under the brand name KORSUVA
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Subscribe To Our Newsletter & Stay Updated
